Sort
10,766 grants matching “checkpoint inhibitor”
Molecular Digital CytoImaging for Leukemia Drug Screening
$567,934Tothu Q Vu · Oregon Health & Science University · R01 · FY2019 · CA
G alpha-q/11 Signaling and Inhibition in Ocular Melanoma
$567,921Kendall Jay Blumer · Washington University · R01 · FY2022 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
$567,912Jie Wu · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2023 · CA
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment
$567,838Mizuki Nishino · Brigham And Women'S Hospital · R01 · FY2020 · CA
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment
$567,838Mizuki Nishino · Brigham And Women'S Hospital · R01 · FY2021 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$567,683Alejandro V Villagra · Georgetown University · R01 · FY2024 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
$567,204Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2024 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$567,157Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA
Endogenous Circular RNAs limit abemaciclib anti tumor immune responses
$567,059Jlenia Guarnerio · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer
$567,039Anant Madabhushi · Emory University · R01 · FY2022 · CA
Stanford Project 2
$566,735Calvin J Kuo · University Of California, San Francisco · U54 · FY2019 · CA
Strategies for Therapeutic Cancer Vaccine Clinical Trials
$566,341Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
$566,338Iman Osman · New York University School Of Medicine · R01 · FY2020 · CA
Nanovaccine platforms to combat pancreatic cancer
$566,261Balaji Narasimhan · Iowa State University · U01 · FY2017 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment
$566,138William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment
$566,138William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Bottlebrush polymer prodrugs for targeted delivery of combination therapies and in vivo imaging of pharmacological response
$566,131Jeremiah Allen Johnson · Massachusetts Institute Of Technology · R01 · FY2024 · CA
Mechanism of estrogen independent proliferation in ER+ breast cancer cells
$565,951Aritro Nath · Beckman Research Institute/City Of Hope · U01 · FY2023 · CA
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors
$565,936Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2023 · CA
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer
$565,815Kristin J Lastwika · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
Targeting Amino Acid Metabolism in Glioblastoma
$565,760Jeremy N Rich · Univ Of North Carolina Chapel Hill · R01 · FY2025 · NS
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
$565,730J. Silvio Gutkind · University Of California, San Diego · R01 · FY2021 · CA
Immune correlates of LTBI in HIV-exposed infants
$565,708Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2024 · AI
Epigenetic regulation of T cell differentiation during infection
$565,557John Justin Milner · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
$565,439Timothy R Donahue · University Of California Los Angeles · R01 · FY2023 · CA